2016 ACVIM Forum Research Abstract Program

A total of 23 dogs were enrolled. Eight cases were excluded due to euthanasia (n = 3), lack of follow up for second sample (n = 3), GC dose <0.5 mg/kg/day at time of second sample collection (n = 1), and change in GC dose < 1 week before second sample collection (n = 1). Fifteen cases met the inclusion criteria. Of the 15 cases enrolled reasons for chronic GC administration included: immune mediated thrombocytopenia (n = 4), immune mediated hemolytic anemia (n = 4), protein losing enteropathy (n = 3), histiocytic sarcoma (n = 1), suspected immune mediated pancytopenia (n = 1), myelofibrosis (n = 1), and mast cell tumor (n = 1). The median Spec cPL concentrations for pre and post GC administration were 68 lg/L (30 -1,997 lg/L) and 165 lg/L (30 -1,628 lg/ L), respectively. There was no statistically significant difference of serum Spec cPL concentrations between baseline and post GC therapy of ≥ 3 weeks in this group of patients (P = 0.19; Figure 1) .